Teva Pharmaceutical Industries buys Auspex Pharmaceuticals for $3.4 billion

Teva Pharmaceutical Industries Ltd announced that it would buy US neurology drug Company Auspex Pharmaceuticals, Inc. for an equity value of $3.4 billion. Auspex’s main product, SD-809, is being developed for the treatment of chorea – an abnormal involuntary movement associated with Huntington’s disease, tardive dyskinesia and Tourette syndrome. SD-809 for Huntington’s is expected to win regulatory approval and be launched commercially in 2016.